India, July 23 -- Shares of Medpace Holdings, Inc. (MEDP) were soaring over 16% after the company announced financial results for the second quarter that ended on June 30, 2026, reflecting 17.2% revenue growth and a lift in its full-year 2026 guidance.
Let us unpack the specifics.
Company Profile
Medpace is a full-service clinical contract research organisation (CRO) providing end-to-end development services to biotech, pharmaceutical and medical device companies.
It specializes in complex trials across oncology, cardiology, metabolic disease, and rare disorders, leveraging an integrated model to accelerate timelines while ensuring quality and compliance.
Second Quarter 2026 Results
For the second quarter of 2026, Net income increased...